Public Release: 

Total annual hospital costs could be reduced by rapid candidemia identification

Future Science Group

IMAGE?

IMAGE: This is the Future Science Group logo. view more

Credit: Future Science Group

8 April, 2015 - A new study describes a model that estimates the economic consequences of using the T2Candida® Panel (a novel diagnostic product that provides Candida detection) as an adjunct to the current blood culture-based diagnostic strategy in a high-risk hospital patient cohort. It estimates that a typical hospital could save as much as $5,858,448 in total annual hospital costs. The study was published online ahead of print in Future Microbiology.

Candida species are a lethal form of common bloodstream infections that cause sepsis. They are associated with high patient mortality and excess inpatient costs because growth-based detection of Candida can delay treatment decisions. Improvements in outcomes are dependent on early identification of candidemia and timely administration of appropriate antifungal therapy. The T2Candida Panel is the first diagnostic test to provide species-specific Candida detection and identification directly from whole blood in 3 to 5 hours, without the need for blood culture.

"We are greatly encouraged by the benefits these data show for the early detection of Candida with our T2Candida Panel," said John McDonough, chief executive officer of T2 Biosystems. "The findings from this study demonstrate not only significant reduction in hospital costs, but most importantly, the potential to save so many patient lives by providing faster diagnostic results -- supporting our goal of changing the paradigm in sepsis diagnosis. We look forward to working closely with the medical community to help implement this important change."

Using a decision tree model, the economic effect of using this diagnostic strategy over 1 year in a hospital setting was calculated. It also calculated Candida-related deaths per hospital could be reduced by 60.6%.

"Hospitals need to reduce the burden of bloodstream infections that cause sepsis in high risk patients, such as those with compromised immune systems. This new and interesting study estimates that that use of this diagnostic test could not only reduce hospital costs, but also reduce mortality rates," said Natasha Leeson, Commissioning Editor of Future Microbiology.

The article is freely available online at http://www.futuremedicine.com/doi/abs/10.2217/fmb.15.29 and will appear in an upcoming print edition of the journal.

###

Notes for editors

About Future Microbiology

The journal publishes original research, reviews and opinion pieces that cover all aspects of microbiological sciences, including virology, bacteriology, parasitology and mycology. Essential information is delivered in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this increasingly important and vast area of research.

Future Microbiology has an impact factor of 3.819, which ranks it 27th by impact factor out of 119 journals in the Microbiology category. The journal is indexed by Biobase, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Biotechnology Citation Index®, CAB abstracts, Chemical Abstracts, EMBASE/Excerpta Medica, Journal Citation Reports/Science Edition®, MEDLINE/Index Medicus, Science Citation Index Expanded™ (SciSearch®) and Scopus.

To find out more about Future Microbiology, please visit our website: http://www.futuremedicine.com/loi/fmb

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.futuresciencegroup.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.